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Abstract
Background: Formyl peptide receptor 1 (FPR1) is a G protein-coupled receptor mainly expressed by the cells of
myeloid origin, where it mediates the innate immune response to bacterial formylated peptides. High expression of
FPR1 has been detected in various cancers but the function of FPR1 in tumorigenesis is poorly understood.
Methods: Expression of FPR1 in neuroblastoma cell lines and primary tumors was studied using RT-PCR, western
blotting, immunofluorescence and immunohistochemistry. Calcium mobilization assays and western blots with
phospho-specific antibodies were used to assess the functional activity of FPR1 in neuroblastoma. The tumorigenic
capacity of FPR1 was assessed by xenografting of neuroblastoma cells expressing inducible FPR1 shRNA, FPR1
cDNA or control shRNA in nude mice.
Results: FPR1 is expressed in neuroblastoma primary tumors and cell lines. High expression of FPR1 corresponds
with high-risk disease and poor patient survival. Stimulation of FPR1 in neuroblastoma cells using fMLP, a selective
FPR1 agonist, induced intracellular calcium mobilization and activation of MAPK/Erk, PI3K/Akt and P38-MAPK signal
transduction pathways that were inhibited by using Cyclosporin H, a selective receptor antagonist for FPR1. shRNA
knock-down of FPR1 in neuroblastoma cells conferred a delayed xenograft tumor development in nude mice,
whereas an ectopic overexpression of FPR1 promoted augmented tumorigenesis in nude mice.
Conclusion: Our data demonstrate that FPR1 is involved in neuroblastoma development and could represent a
therapy option for the treatment of neuroblastoma.
Keywords: FPR1, Formyl peptide receptor 1, Neuroblastoma, Inflammation
Background
Neuroblastoma (NB) is a tumor of the peripheral ner-
vous system, and is a common and deadly childhood
tumor [1]. Despite extensive treatment, including
chemotherapy, surgery, radiation therapy and immuno-
therapy, the survival rate among high-risk patients is less
than 50 % [2, 3]. Hence, there is a great need for new
therapies, particularly those based on a biological under-
standing of tumor development.
N-formyl peptide receptors, of which three have been
described in humans (FPR1, FPR2 and FPR3), are in-
volved in the regulation of innate immune responses [4].
FPRs are seven-transmembrane G protein-coupled
receptors that were originally described in immune cells,
and are important for the induction of inflammation and
immune cell activation in response to N-formyl peptides
produced by bacteria during infections [5]. FPR expres-
sion was subsequently shown in non-hematopoietic cells
and tissues where the receptors are involved in tissue re-
generation and wound healing [5]. Several studies have
suggested a role for FPRs in the progression of tumors
of different origin [6–11]. The involvement of FPRs in
tumorigenesis seems to be context-specific. For instance,
in gastric cancer a high expression of FPR1was associ-
ated with advanced disease and poor survival [11], while
another study reported FPR1 to be a tumor suppressor
by inhibition of angiogenesis [12]. In glioma, FPR was
shown to mediate tumor cell chemotaxis, proliferation
and the stimulation of angiogenesis, and to also induce
an invasive phenotype, whereas in melanoma FPR
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promoted NK cell migration and inhibited tumor growth
[6, 9, 13, 14].
In this study, we investigated the functional role of
FPR1 in neuroblastoma development, and showed that
high FPR1 expression is associated with high-risk disease
and is important for neuroblastoma tumorigenesis.
Methods
Bioinformatics
FPR1 gene expression data were downloaded from R2:
Genomics Analysis and Visualization Platform [15]
(http://r2.amc.nl), and the R2 web-based application was
used to generate Kaplan-Meier survival curves.
Cell lines and reagents
The human neuroblastoma cell lines (SK-N-FI, SHEP-1,
SK-N-BE (2), SK-N-SH, SK-N-AS, SH-SY5Y, SK-N-DZ)
were purchased from the American Type Culture Col-
lection (ATCC) (Table 1). The cells were cultured in hu-
midified air with 5 % CO2 at 37 °C in RPMI-1640
medium with L-glutamine and sodium bicarbonate
(R8758, Sigma-Aldrich Chemie GmbH, Steinheim,
Germany), and supplemented with 10 % FBS. N-Formyl-
L-methionyl-L-leucyl-L-phenylalanine (fMLP) was pur-
chased from Sigma-Aldrich (F3506, St. Louis, MO, USA)
and Cyclosporin H from Enzo Life Sciences (ALX-380-
286, Farmingdale, NY, USA).
Human tissue samples
Primary neuroblastoma samples were obtained during
surgery, snap-frozen in liquid nitrogen and transferred to
−80 °C for future analysis. Twenty-seven neuroblastoma
samples derived from children of different ages and all
clinical stages, including different biological subsets
(MYCN amplification, 7 of 27; 1 p deletion, 9 of 27) were
analyzed. Ethical approval was obtained from the Karo-
linska University Hospital Research Ethics Committee.
Western blot analysis
Homogenized tissue specimens and cells were lysed dir-
ectly in a RIPA lysis buffer (89901, Pierce Biotechnology,
Rockford, IL, USA) with protease inhibitor cocktail
(04693124001, Roche Applied Science, Basel, Switzerland)
and Halt phosphatase inhibitor cocktail (78420, Pierce
Biotechnology). Moreover, a mixture containing the
NuPAGE LDS Sample Buffer (NP0008, Life Technologies,
Carlsbad, CA, USA), NuPAGE Sample Reducing Agent
(NP0004, Life Technologies) and distilled water were
added to lysates. The samples were heated to 70 °C for
10 min, and equal amounts of protein were loaded into
NuPAGE Novex 4-12 % Bis-Tris gel (NP0335PK, Life
Technologies). Gel electrophoresis and blotting onto
PVDF membrane (LC2005, Life Technologies) were per-
formed according to the NuPAGE Technical Guide (Invi-
trogen). Tris buffered saline with 0.1 % Tween-20 (93773,
Sigma) and 5 % Bio-Rad Blotting-grade blocker (170–
6404, Hercules, CA, USA) were used for blocking, while
primary and secondary antibodies were diluted in the
blocking buffer. Membranes were probed with antibodies
against FPR1 (ab113531, Abcam, Cambridge, UK), p44/42
MAPK (Erk1/2) (4695, Cell Signaling Technology, Dan-
vers, MA, USA), Phospho-p44/42 MAPK (Erk1/2) (4370,
Cell Signaling Technology, Danvers, MA), Akt (9272, Cell
Signaling Technology), Phospho-Akt (9271, Cell Signaling
Technology), P38-MAPK (9212, Cell Signaling Technol-
ogy) and Phospho-P38-MAPK (9211, Cell Signaling Tech-
nology). Concentrations of the antibodies were 1:500,
1:1500, 1:2000, 1:1000, 1:1000, 1:1000 and 1:1000, respect-
ively. Anti-beta Actin antibody (ab8227, Abcam) in a dilu-
tion of 1:5000 was used as a loading control. Goat Anti-
Rabbit IgG H&L (HRP) antibodies (ab6721, Abcam) in a
dilution of 1:5000 served as secondary antibodies. Super-
Signal West Pico Chemiluminescent Substrate (34080 F,
Pierce Biotechnology) was used for detection, and images
were acquired on a Fujifilm LAS-3000 Imager.
Reverse transcription PCR
Total RNA was isolated from pelleted cells and tumor
tissue using the Qiagen RNeasy Mini Kit (74104, Hilden,
Germany) according to the manufacturer’s protocol. The
quantity and quality of the extracted RNA was deter-
mined with the use of a spectrophotometer NanoDrop
ND-1000 (Wilmington, DE, USA). cDNA was synthe-
sized from 1 μg of total RNA using the QuantiTect Re-
verse Transcription Kit (205310, Hilden) according to
the manufacturer’s protocol. PCR was performed in a
25 μl reaction mixture containing 2 μl of cDNA (from
isolated RNA), 12.5 μl of the JumpStart REDTaq® Ready
Mix (Sigma-Aldrich, P0982), 0.5 μl of 10 μM forward
and reverse primers, and 9.5 μl of ddH2O. The reactions
Table 1 Characteristics of the cell lines used in this study
SK-N-FI SHEP-1 SK-N-BE(2) SK-N-SH SK-N-AS SH-SY5Y SK-N-DZ
MYCN amplification - - + - - - +
MDR phenotype + - + + + - -
1p deletion - - + - + - -
11q deletion - - - - + - +
MDR multiple drug resistance
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were performed in a BioRad T-100 thermal cycler with
the following conditions: initial denaturation at 95 °C for
2 min, denaturation at 95 °C for 30 s, annealing at 58 °C
for 30 s and extension at 72 °C for 2 min. In total, 35 cy-
cles were conducted with a final extension at 72 °C for
10 min. PCR products were electrophoresed on 2 %
agarose gel and visualized under UV light. The se-
quences of PCR primers were FPR1 forward: 5′-TGG
GAG GAC ATT GGC CTT TC-3′; and reverse: 5′-
GGA TGC AGG ACG CAA ACA C-3′ (PrimerBank ID
36951095c1, http://pga.mgh.harvard.edu/primerbank/
index.html); β-actin forward: 5′-CTC GAC ACC AGG
GCG TTA T-3′; and reverse: 5′-CCA CTC CAT GCT
CGA TAG GAT-3′.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue sections
were deparaffinized in xylene and graded alcohols, hy-
drated and washed in a phosphate-buffered saline (PBS).
After antigen retrieval in a sodium citrate buffer (pH 6)
in a microwave oven, the endogenous peroxidase was
blocked by 0.3 % H2O2 for 15 min. Sections were incu-
bated overnight at 4 °C with a primary antibody
(ab113531, Abcam). As a secondary antibody, the anti-
rabbit-horseradish peroxidase (HRP) SuperPicTure Poly-
mer detection kit was used (87–9663, Zymed-Invitrogen,
San Francisco, CA, USA). A matched isotype control
was also used as a control for nonspecific background
staining.
Immunofluorescence
For immunofluorescence studies, cells were grown on fi-
bronectin coated chamber slides (Nunc, Roskilde,
Denmark) for 24 h. Cultures were then washed and fixed
with 2 % paraformaldehyde for 30 min. After washing with
a PBS buffer, rabbit anti-FPR1 antibodies (described above)
were incubated with cultures overnight at 4 °C. After
rinsing in PBS, cultures were incubated with goat anti-
rabbit IgG secondary antibodies conjugated with Alexa 488
(A-11008, Life Technologies, Eugene, OR, USA).
Calcium mobilization assay
SK-N-SH cells (2.5x104 cell per well) were seeded into
an 8 well μ-Slide (80826, iBidi GmbH, Munich,
Germany) and incubated overnight in a complete growth
medium. The next day the cells were washed and pre-
loaded with 20 μM Cal-520 (21131, AATBio, Sunnyvale,
CA, USA) in HHBS with 0.04 % Pluronic® F-127 (20053,
AATBio). After 90 min of incubation at 37 °C, a dye so-
lution was replaced with HHBS and cells were subse-
quently examined with a Leica TCS SP5 confocal
microscope. Before the addition of 10 nM of fMLP, a
baseline was measured. Images were then obtained and
analyzed using the Leica LAS AF software.
Generation of neuroblastoma cells with a differential
expression of FPR1
A plasmid containing a human sequence-verified FPR1
cDNA (Clone ID 3829614) was purchased from Thermo
Fisher Scientific, as well as lentiviral vectors pTRIPZ_con-
trol with a scrambled shRNA (Clone ID RHS4743) and
four different pTripz shRNA clones targeting FPR1 (Clone
Ids V3THS_390191, V3THS_390189, V3THS_413003,
V3THS_113957). Lentiviral helper packaging plasmid
psPAX2 (Plasmid ID 12260) and envelope plasmid
pMD2.G (Plasmid ID 12259) were purchased from
Addgene.
All primers used were purchased from Integrated
DNA technologies (IDT), with the exception of the
RFP_2A_rev primer, which was purchased from Sigma.
LentiX HEK-293 T cells were purchased from Clone-
tech (632180, Mountain View, CA, USA) and grown at
37 °C and 5 % CO2 in Dulbecco’s Modified Eagle
Medium (11966–025, Gibco™, Paisley, UK), supple-
mented with 10 % FBS; 100 μg/mL of streptomycin and
100 U/mL of penicillin. SK-N-AS cells were ordered
from the American Type Culture Collection (ATCC)
(CRL-2137) and grown at 37 °C and 5 % CO2 in a
RPMI-1640 medium (21875–034, Gibco™) supplemented
with 10 % FBS, 100 μg/mL of streptomycin and 100 U/
mL of penicillin.
A lentiviral plasmid expressing turbo red fluorescent
protein (tRFP) and FPR1 cDNA separated by a 2A se-
quence (pTripz_RFP_2A_FPR1) was constructed by
amplification of a tRFP fragment from a 10 ng pTripz_-
control plasmid template using forward primer RFP_fwd
(CGT TTA GTG AAC CGT CAG ATC GCA CCG GTC
GCC ACC ATG AG) and reverse primer RFP_2A_rev
(GTC TCC TGC TTG CTT TAA TAG AGA GAA GTT
AGT AGC TCC AGA TCC TCT GTG CCC CAG TTT
GCT A). FPR1 cDNA was amplified from a cDNA plas-
mid template (1 μl of glycerol bacterial stock) using a
PAGE purified forward primer 2A_FPR1_fwd (GCT
ACT AAC TTC TCT CTA TTA AAG CAA GCA GGA
GAC GTG GAA GAA AAC CCA GGT CCT ATG GAG
ACA AAT TCC TCT CTC CC) and reverse primer
FPR1_rev (GCG GAG GCC ACG CGT CTA CTT TGC
CTG TAA CTC CAC C). PTripz_control plasmid was
cleaved using restriction enzymes AgeI_HF (R3552S,
Ipswich, MA, USA) and MluI (R0198S) purchased from
New England Biolabs (NEB), and gel purified using a
1 % TAE agarose gel. 100 ng of plasmid backbone was
mixed with the PCR-generated tRFP and FPR1 cDNA
fragments in equimolar amounts and ligated using 2X
Gibson mix (E2611S, NEB). A 2 μl ligation mixture was
used to transfect XL10 gold ultracompetent cells
(200314, NEB) and spread on 100 μM Amp agar plates.
The resultant colonies were picked, amplified and puri-
fied using alkaline lysis and precipitated using 10 %
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PEG-6000. All plasmids were sequence verified prior to
transfection.
Lipofectamine LTX with plus reagent (15338100) was
purchased from Life Technologies. Approximately 1 mil-
lion LentiX Hek293T cells were resuspended in 5 ml of
Opti-MEM® (31985–047, Gibco™). Plasmid DNA (1 μg
of psPAX2, 1 μg of shRNA or control plasmid and
0.5 μg of pMD2.G) were mixed with 2.5 μl plus reagent
and incubated for 5 min at room temperature. Next,
7.5 μl of lipofectamine LTX was added and the samples
were incubated for an additional 30 min at RT before
being added to the cells. Approximately 48 h post-
transfection, the cell culture media was removed using a
5 ml syringe, filtered through 0.45 μm SUPOR syringe
filters (4654, Ann Arbor, MI, USA) ordered from the Pall
Corporation and stored at −80 °C.
Approximately 100,000 SK-N-AS cells were seeded per
well in a 24-well plate in 1 ml RPMI-1640 medium sup-
plemented with 10 % FBS, a penicillin/streptomycin so-
lution and L-glutamine. Different amounts of virus-
containing filtered Opti-MEM® were added to the cells
(200 μl, 50 μl and 12.5 μl), and the cells were incubated
at 37 °C for 48 h. After the recovery period, the infected
cells were selected by adding puromycine to the
complete RPMI-1640 medium at a final concentration of
0.5 μg/ml. In order to minimize off-target effects due to
multiple integration, only wells that contained less than
a few hundred CFU (colony forming units) were used.
Xenograft experiment
In vivo xenograft studies were performed using 10 im-
munodeficient NMRI nu/nu mice (Taconic, Ejby,
Denmark) per construct. Mice were subcutaneously
injected in the flank with 0.9 x 106 cells in 100 μl RPMI-
1640. The mice received doxycycline in the water at a
concentration of 1 μg/ml. Tumors were measured three
times per week with digital calipers and the volume was
calculated by the formula width2 × length × 0.44. The
animals were sacrificed after they developed a tumor
volume ≥ 1 cm3. The excised tumors were divided into
two parts, which were then formalin-fixed and snap
frozen. The animal experiments were approved by the
Regional Ethics Committee (Stockholm Northern Board)
for Animal Research (approval ID: N391/11), appointed
and put under the control of the Swedish Board of Agri-
culture and the Swedish Court. The animal experiments
presented herein were in accordance with the proper na-
tional regulations (SFS 1988:534, SFS 1988:539, and SFS
1988:541).
Statistical analysis
Statistical analysis and Kaplan-Meier curves were pre-
pared using a SigmaPlot version 13.0 (Systat Software,
San Jose, CA, USA). Experimental groups were com-
pared using a log-rank test.
Results
High-level expression of FPR1 is a negative prognostic
factor for neuroblastoma patient survival
Using publicly available expression cohorts, we analyzed
the expression levels of FPR1 and the correlation to overall
survival in neuroblastoma patients (Fig. 1). FPR1 corre-
lated to poor survival in the majority of expression cohorts
analyzed (R2: Genomics Analysis and Visualization Plat-
form: http://r2.amc.nl) [15].
Also, the expression level of FPR1 was analysed in a be-
nign neurofibroma and neural crest revealing a significant
lower expression levels compared to neuroblastoma
(Fig. 1). Immunohistochemistry and immunofluorescence
showed a high expression of FPR1 in neuroblastoma tissue
samples and cell lines, respectively (Fig. 2b, c). The stain-
ing was localized to the cytoplasm and plasma membrane
of tumor cells. Furthermore, all neuroblastoma cell lines
analyzed exhibited a significant expression of FPR1, as
shown by RT-PCR and western blotting (Fig. 2a).
FPR1 signaling mobilizes Ca2+ and phosphorylation of
Erk1/2, Akt and P38
To investigate the function of FPR1 in neuroblastoma,
we stimulated neuroblastoma cells with the FPR1 agonist
fMLP. The addition of 10 nM fMLP to SK-N-SH cells
induced a rapid increase of intracellular Ca2+ (Fig. 3).
No differences in Ca2+ mobilization were observed when
SK-N-SH cells were pre-incubated with the calcium che-
lator EDTA, thus suggesting an intracellular activation
of Ca2+.
The addition of fMLP (10nM) to serum-starved SH-
SY5Y, SK-N-BE(2) and SK-N-AS resulted in a rapid
transient phosphorylation of Akt, Erk1/2 and P38
(Fig. 4a). Preincubation of the cells for 15 min with
the selective FPR1 antagonist, cyclosporin H, abol-
ished Erk1/2 and Akt phosphorylation induced by the
addition of fMLP (Fig. 4b).
FPR1 promotes neuroblastoma tumorigenesis
To assess the role of FPR1 in tumor formation in vivo,
we developed a set of SK-N-AS cell clones with either
an overexpression or shRNA-mediated knock-down of
FPR1. Three groups of nude mice, with 10 animals in
each group, were injected with control shRNA, FPR1
shRNA and FPR1 cDNA expressing cells in the hind
flanks, and tumor formation was monitored. The time to
tumor take, defined as the number of days for a tumor
in the animal to reach a volume of 0.2 and 0.5 cm3, was
prolonged in mice injected with shRNA knock-down
cells compared to mice receiving random shRNA cells
(CTR) (p < 0.001) (Fig. 5a, b). For SK-N-AS FPR1
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knockdown cells, the median time to a tumor volume of
0.2 cm3 was more than 50 % longer compared to CTR
(55 vs. 36 days) (Fig. 5a). SK-N-AS cells with a forced
overexpression of FPR1 developed tumors in nude mice
significantly earlier compared to CTR tumors (p < 0.001)
(Fig. 5a, b).
Discussion
N-formyl peptides are cleavage products of bacterial and
mitochondrial proteins that can attract leukocytes to
sites of infection or tissue damage [16, 17]. Formyl pep-
tide receptor 1 (FPR1) is a cell surface receptor originally
described in leukocytes, that binds and is activated by
N-formyl peptides, important for the induction of in-
flammation and immune cell activation. More recently,
FPR1 has also been detected in cells of non-myeloid ori-
gin such as, smooth muscle cells, lens epithelial cells, fi-
broblasts, etc. indicating the involvement of the receptor
in a wide variety of inflammatory responses [5, 16, 18,
19].
Aberrant expression of FPR1 has been detected in
various adult cancers and increased expression of FPR1
in tumors has previously been reported as a negative
prognostic factor in patients with gastric cancer, astrocy-
toma and melanoma [10, 11, 20].
In the present study, we investigated the role of FPR1
in the biology of NB. When using the publicly available
“R2: Genomics analysis and visualization platform” [15]
with two expression arrays of data from 88 and 102 NB
samples, respectively, we discovered that a high FPR1
mRNA expression was correlated with a poor prognosis
(Fig. 1). Neurofibroma and neuroblastoma both arise
from the neural crest. The level of FPR1 expression was
shown to be lower in benign neurofibroma and normal
neural crest than in the neuroblastoma, indicating a role
of FPR1 in the process of tumorigenesis. Interestingly,
FPR1 expression in high-risk tumors, i.e. MYCN-
amplified, did not differ from non-amplified MYCN tu-
mors (data not shown) proposing that FPR1 can be used
as an independent prognostic marker for overall survival
in NB.
By mRNA and western blot analyses, we found that
FPR1 was expressed in seven different NB cell lines. Al-
though the different NB cell lines displayed a differential
expression of FPR1, no direct relationship between the
expression and different genetic aberrations or biological
features were observed (Fig. 2a and Table 1)
Recently, Huang et al. showed that glioblastoma cells
expressing FPR1 exhibit a highly invasive and malignant
phenotype [9, 21]. Additionally, Szczepanek and co-
authors demonstrated that FPR1 expression is associated
with drug resistance in patients with acute lymphoblastic
leukemia [22].
By immunohistochemistry, we analyzed neuroblastoma
primary tumors from different biological subsets and
clinical stages, and FPR1 expression was detected in all
the samples investigated (n = 27) (Fig. 2b), independent
of any biological characteristics or clinical stage.
The interaction between FPR1 and its’ ligands triggers
a cascade of second messengers through the activation
of calcium influx including PI3-kinase, MAP-kinases and
NF-kB [23–25]. In order to determine the functional sig-
nificance of FPR1expression in NB, we incubated the
cells with fMLP, a bacterial peptide that induces a sig-
nificant activation of FPR1 at nanomolar concentrations
[5].
Stimulation of neuroblastoma cells with fMLP induced
a rapid release of intracellular Ca2+ and activation of
PI3K/Akt and ERK1/2 signalling (Fig. 3). Similar effects
of FPR1 stimulation have recently been described in
both normal and tumor cells [18, 20, 26, 27]. Calcium is
a ubiquitous second messenger and in cancer it has been
implicated in numerous important features of tumori-
genesis, including angiogenesis, motility, proliferation
and migration [28].
Mitogen-activated protein kinase (MAPK) cascades
are key signaling pathways involved in the regulation of
normal cell proliferation and survival. These transduc-
tion pathways transmit and amplify signals mediated by
various growth factors and ligands for G protein-
coupled receptors such as fMLP [26].
Activation of the mitogen-activated kinases/extracellu-
lar signal-regulated kinases (ERK1/2) has been fre-
quently observed in NB [29].
To further investigate the functional response of the
FPR1 activation, we performed a set of Western blots
using phospho-specific antibodies. The phosphorylation
of Erk 1/2 MAP kinases and P38 MAP kinase was evi-
dent upon stimulation with fMLP (Fig. 4a).
There is a large body of evidence that the PI3K/Akt/
mTOR pathway plays an important role in the develop-
ment and progression of NB (reviewed in [30]). The acti-
vation of Akt triggers many downstream signaling
cascades attributed to tumor growth and survival
(reviewed in [31]). We and others have previously shown
(See figure on previous page.)
Fig. 1 FPR1 gene expression and NB overall survival. a High expression of FPR1 in NB is significantly associated with a worse survival. Data were
obtained from “R2: Genomics analysis and visualization platform” [http://r2.amc.nl]. Two datasets provided by Versteeg (n = 88) and Seeger
(n = 102) were used. b Dot plot representing higher expression of FPR1 in Versteeg cohort compared to neural crest tissue and benign
neurofibroma. Data were obtained from “R2: Genomics analysis and visualization platform” [http://r2.amc.nl]
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the specific expression of phosphorylated Akt and
mTOR in NB tissue from a variety of clinical and bio-
logical stages [29, 32]. In the present work we revealed
that the stimulation of NB cells with 10 nM of fMLP
results in the phosphorylation of Akt with a peak lying
in the interval between 2 and 30 min, which is consist-
ent with previously reported studies with glioblastoma
[6, 27] and astrocytoma [20].
After demonstrating that the receptor activation in-
duces signal transduction in NB cells in vitro we wanted
to assess the functional significance of FPR1 expression
in NB in vivo. We therefore xenografted SK-N-AS cells
transfected with lentiviral constructs containing control
shRNA, FPR1 shRNA and FPR1 cDNA, respectively.
We observed that animals injected with stable high
FPR1 expressing NB cells presented tumors more rapidly
compared to the control group of animals and the group
with silenced FPR1 (Fig. 5a, b). In addition, nine out of
ten animals with a high expression of the receptor
reached the experimental endpoint (tumor volume ≥
1 cm3) by day 36 after injection, while none of the ani-
mals from the other groups reached the endpoint by day
100 after injection (Fig. 5c).
Our data are in line with results reported in a human
glioblastoma model, in which FPR1 expressing U-87
cells that were either silenced by siRNA or inhibited by
FPR1 antagonist exhibited a delayed tumorigenicity in
vitro [6, 20, 33].
How elevated FPR1 expression in NB may contribute
to tumorigenicity is not known. The induction of FPR1
may trigger a wide variety of effects attributed to tumor
growth such as increased vascular permeability and
(See figure on previous page.)
Fig. 2 FPR1 is expressed in NB cell lines and primary tumors. a Western blotting detected a protein band of approximately 38 kDa corresponding
to FPR1 in all NB cells investigated. Additionally, RT-PCR analysis revealed FPR1 expression in 7 NB cell lines. b Immunohistochemistry showing
specific expression of FPR1 in tumor cells of a primary human neuroblastoma. (upper panel, HE staining, 20x and 60x; middle panel, anti-human
FPR1 staining, 20x and 60x; lower panel, isotype control, 20x and 60x) c Immunofluorescence staining of FPR1 (green) in SK-N-BE(2) cells
Fig. 3 FPR1 stimulation promotes intracellular Ca2+ mobilization. a Changes in intracellular calcium level were measured by confocal scanning
microscope using green fluorescent calcium-binding dye. After baseline measurement, fMLP was added to the cells’ media and subsequent
fluctuations of green fluorescence were monitored. b Pretreatment with EDTA. The arrow depicts time of fMLP addition
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angiogenesis, chemotaxis, cell adhesion, as well as cell
survival and proliferation [6, 8]. Besides fMLP, ligands
for FPR1 also include non-microbial endogenous
host-derived peptides such as mitochondrial formy-
lated peptides fMMYALF, fMLKLIV and fMFADRW,
Annexin A1 and Cathepsin G [5, 34, 35], that may be
released by necrotic cells within the tumor
microenvironment.
Recently, several reports have shown that tumor
cells have co-opted some of the signaling molecules
of the innate immune system, such as arachidonic
metabolites [36], chemokines [37], alarmins [38] and
their receptors for invasion, migration and metastasis
[21]. We assume that FPR1 expressed by NB cells
may be activated by formylated peptides released from
the mitochondria or by other compartments of nec-
rotic tumor cells, locally acting as trophic factors
which promote FPR1-driven inflammatory signaling
pathways, amplified growth and invasiveness. Hence,
the recent development of FPR1 antagonists modulat-
ing the inflammatory processes makes FPR1 a promis-
ing target for adjuvant NB therapy [39].
Fig. 4 Activation of signal transduction pathways in response to the stimulation of FPR1. a Phosphorylation of Erk1/2, Akt and P38-MAPK occurred
after stimulation of NB cells with 10 nM of fMLF. Numbers represent densitometric values of bands. b Incubation of the cells with Cyclosporine H
blocks ERK1/2 phosphorylation
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Conclusions
In summary, we have shown that FPR1 is expressed in
human NB tissue and that the receptor is functionally
active in human NB cells. Furthermore, the inhibition of
FPR1 activity in NB cells resulted in a decreased tumor
growth in a xenograft model while overexpression re-
sulted in an increased tumor load, suggesting a role for
FPR1 in the development of an aggressive phenotype.
Our results are supported by microarray survival data
from human tumor samples, demonstrating that a high
FPR1 expression is associated with significantly lowered
overall patient survival.
Pharmacological intervention that targets FPR1 in NB
may become an interesting adjuvant therapy for children
with NB but further preclinical studies are warranted.
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images for Fig. 2. Lower gel represents no RT controls for all cell lines
(lanes 1–7) and no template control (lane 8). (TIF 2142 kb)
Additional file 2: Figure S2. Complete WB membranes for Fig. 4.
(TIF 926 kb)
Additional file 3: Figure S3. Complete WB membranes for Fig. 4.
(TIF 1188 kb)
Abbreviations
cDNA: complementary DNA; CTR: control; FBS: fetal bovine serum; fMLP:
N-Formyl-L-methionyl-L-leucyl-L-phenylalanine; FPR1: formyl peptide
receptor 1; HHBS: Hank’s Balanced Salt Solution; mRNA: messenger RNA; NB:
neuroblastoma; PBS: phosphate-buffered saline; RFP: red fluorescent protein;





This study was supported by grants from the Northern Norway Regional
Health Authority and the University Hospital of North Norway (SFP996-11),
and Erna and Olav Aakre Foundation for Cancer Research, Tromsø, Norway.
Availability of data and materials
All relevant data are within the paper and its Additional files 1, 2, 3.
Authors’ contributions
IS, COÖ, YF, PK, JIJ and BS conceived the study and designed the
experiments. IS, COÖ, JIJ and BS performed the experiments. IS, YF, PK, JIJ
and BS analyzed the data and prepared the figures. IS, COÖ, YF, JIJ and BS
wrote the paper. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable
Ethics approval and consent to participate
A series of primary NB samples was collected for which written or verbal
consent was obtained according to the ethical permits approved by the
Karolinska University Hospital Research Ethics Committee (Approval no 2009/
1369-31/1 and 03–763)
The animal experiments were approved by the Regional Ethics Committee
(Stockholm Northern Board) for Animal Research (approval ID: N391/11),
appointed and put under the control of the Swedish Board of Agriculture
and the Swedish Court. The animal experiments presented herein were in
accordance with the proper national regulations (SFS 1988:534, SFS 1988:539,
and SFS 1988:541).
Author details
1Molecular Inflammation Research Group, Department of Medical Biology,
Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
2Childhood Cancer Research Unit, Department of Women’s and Children’s
Health, Karolinska Institutet, Stockholm, Sweden. 3Endocrinology Research
Group, Department of Clinical Medicine, Faculty of Health Sciences,
University of Tromsø, Tromsø, Norway. 4Department of Medical Biology,
Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
5Department of Laboratory Medicine, University Hospital of North Norway,
Tromsø, Norway.
Received: 9 November 2015 Accepted: 11 July 2016
References
1. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–11.
2. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B.
Treatment and outcomes of patients with relapsed, high-risk
neuroblastoma: results of German trials. Pediatr Blood Cancer.
2011;56:578–83.
3. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Hogarty M,
Committee COGN. Children’s Oncology Group’s 2013 blueprint for research:
neuroblastoma. Pediatr Blood Cancer. 2013;60:985–93.
4. Chen K, Liu M, Liu Y, Yoshimura T, Shen W, Le Y, Durum S, Gong W, Wang C, Gao
JL, et al. Formylpeptide receptor-2 contributes to colonic epithelial homeostasis,
inflammation, and tumorigenesis. J Clin Invest. 2013;123:1694–704.
5. Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a
promiscuous subfamily of G protein-coupled receptors controlling immune
responses. Cytokine Growth Factor Rev. 2006;17:501–19.
6. Zhou Y, Bian X, Le Y, Gong W, Hu J, Zhang X, Wang L, Iribarren P, Salcedo R,
Howard OM, et al. Formylpeptide receptor FPR and the rapid growth of
malignant human gliomas. J Natl Cancer Inst. 2005;97:823–35.
7. Yao XH, Ping YF, Chen JH, Chen DL, Xu CP, Zheng J, Wang JM, Bian XW.
Production of angiogenic factors by human glioblastoma cells following
activation of the G-protein coupled formylpeptide receptor FPR. J
Neurooncol. 2008;86:47–53.
8. Xu CP, Zhang HR, Chen FL, Yao XH, Liang ZQ, Zhang R, Cui Y, Qian C, Bian
XW. Human malignant glioma cells expressing functional formylpeptide
receptor recruit endothelial progenitor cells for neovascularization. Int
Immunopharmacol. 2010;10:1602–7.
9. Huang J, Chen K, Chen J, Gong W, Dunlop NM, Howard OM, Gao Y, Bian
XW, Wang JM. The G-protein-coupled formylpeptide receptor FPR confers a
more invasive phenotype on human glioblastoma cells. Br J Cancer. 2010;
102:1052–60.
10. Chakravarti N, Peddareddigari VG, Warneke CL, Johnson MM, Overwijk WW,
Hwu P, Prieto VG. Differential expression of the G-protein-coupled formyl
Peptide receptor in melanoma associates with aggressive phenotype. Am J
Dermatopathol. 2013;35:184–90.
11. Cheng TY, Wu MS, Lin JT, Lin MT, Shun CT, Hua KT, Kuo ML. Formyl Peptide
receptor 1 expression is associated with tumor progression and survival in
gastric cancer. Anticancer Res. 2014;34:2223–9.
(See figure on previous page.)
Fig. 5 FPR1-dependent tumor development and survival in animal model. Cell lines with different expression level of FPR1 were subcutaneously
injected into mice, and tumor growth was recorded. Kaplan-Meier curves represent the time until tumors reached a volume of 0.2 cm3 (a) and
0.5 cm3 (b). Survival plot (c) shows the difference in survival between animals with high and low expression levels of FPR1 (the criterion for
endpoint was a tumor volume≥ 1 cm3)
Snapkov et al. BMC Cancer  (2016) 16:490 Page 11 of 12
12. Prevete N, Liotti F, Visciano C, Marone G, Melillo RM, de Paulis A. The formyl
peptide receptor 1 exerts a tumor suppressor function in human gastric
cancer by inhibiting angiogenesis. Oncogene. 2015;34:3826–38.
13. Chen DL, Ping YF, Yu SC, Chen JH, Yao XH, Jiang XF, Zhang HR, Wang QL,
Bian XW. Downregulating FPR restrains xenograft tumors by impairing the
angiogenic potential and invasive capability of malignant glioma cells.
Biochem Biophys Res Commun. 2009;381:448–52.
14. Liu J, Li J, Zeng X, Rao Z, Gao J, Zhang B, Zhao Y, Yang B, Wang Z, Yu L,
Wang W. Formyl peptide receptor suppresses melanoma development and
promotes NK cell migration. Inflammation. 2014;37:984–92.
15. R2: microarray analysis and visualization platform [http://r2.amc.nl] Accessed
07 May 2016
16. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN,
Murphy PM. International Union of Basic and Clinical Pharmacology. LXXIII.
Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev.
2009;61:119–61.
17. Bloes DA, Kretschmer D, Peschel A. Enemy attraction: bacterial agonists for
leukocyte chemotaxis receptors. Nat Rev Microbiol. 2015;13:95–104.
18. Schneider EH, Weaver JD, Gaur SS, Tripathi BK, Jesaitis AJ, Zelenka PS, Gao
JL, Murphy PM. The leukocyte chemotactic receptor FPR1 is functionally
expressed on human lens epithelial cells. J Biol Chem. 2012;287:40779–92.
19. VanCompernolle SE, Clark KL, Rummel KA, Todd SC. Expression and function of
formyl peptide receptors on human fibroblast cells. J Immunol. 2003;171:2050–6.
20. Boer JC, Domanska UM, Timmer-Bosscha H, Boer IG, de Haas CJ, Joseph JV,
Kruyt FA, de Vries EG, den Dunnen WF, van Strijp JA, Walenkamp AM.
Inhibition of formyl peptide receptor in high-grade astrocytoma by
CHemotaxis Inhibitory Protein of S. aureus. Br J Cancer. 2013;108:587–96.
21. Huang J, Chen K, Gong W, Zhou Y, Le Y, Bian X, Wang JM. Receptor
“hijacking” by malignant glioma cells: a tactic for tumor progression. Cancer
Lett. 2008;267:254–61.
22. Szczepanek J, Pogorzala M, Jarzab M, Oczko-Wojciechowska M, Kowalska M,
Tretyn A, Wysocki M, Jarzab B, Styczynski J. Expression profiles of signal
transduction genes in ex vivo drug-resistant pediatric acute lymphoblastic
leukemia. Anticancer Res. 2012;32:503–6.
23. Selvatici R, Falzarano S, Mollica A, Spisani S. Signal transduction pathways
triggered by selective formylpeptide analogues in human neutrophils.
Eur J Pharmacol. 2006;534:1–11.
24. Cattaneo F, Guerra G, Ammendola R. Expression and signaling of
formyl-peptide receptors in the brain. Neurochem Res. 2010;35:2018–26.
25. Dorward DA, Lucas CD, Chapman GB, Haslett C, Dhaliwal K, Rossi AG. The role
of formylated peptides and formyl peptide receptor 1 in governing neutrophil
function during acute inflammation. Am J Pathol. 2015;185:1172–84.
26. Rane MJ, Carrithers SL, Arthur JM, Klein JB, McLeish KR. Formyl peptide
receptors are coupled to multiple mitogen-activated protein kinase cascades
by distinct signal transduction pathways: role in activation of reduced
nicotinamide adenine dinucleotide oxidase. J Immunol. 1997;159:5070–8.
27. Boer JC, van Marion DM, Joseph JV, Kliphuis NM, Timmer-Bosscha H, van
Strijp JA, de Vries EG, den Dunnen WF, Kruyt FA, Walenkamp AM.
Microenvironment involved in FPR1 expression by human glioblastomas.
J Neurooncol. 2015;123:53–63.
28. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps
in cancer: changes and consequences. J Biol Chem. 2012;287:31666–73.
29. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt
predicts poor outcome in neuroblastoma. Cancer Res. 2007;67:735–45.
30. King D, Yeomanson D, Bryant HE. PI3King the lock: targeting the PI3K/Akt/
mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr
Hematol Oncol. 2015;37:245–51.
31. Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling
pathway and cancer: an updated review. Ann Med. 2014;46:372–83.
32. Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, Kagedal B,
Eksborg S, Sveinbjornsson B, Kogner P. Inhibitors of mammalian target of
rapamycin downregulate MYCN protein expression and inhibit
neuroblastoma growth in vitro and in vivo. Oncogene. 2008;27:2910–22.
33. Huang J, Hu J, Bian X, Chen K, Gong W, Dunlop NM, Howard OM, Wang JM.
Transactivation of the epidermal growth factor receptor by formylpeptide
receptor exacerbates the malignant behavior of human glioblastoma cells.
Cancer Res. 2007;67:5906–13.
34. Rabiet MJ, Huet E, Boulay F. Human mitochondria-derived N-formylated
peptides are novel agonists equally active on FPR and FPRL1, while Listeria
monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol.
2005;35:2486–95.
35. Yang Y, Liu Y, Yao X, Ping Y, Jiang T, Liu Q, Xu S, Huang J, Mou H, Gong W,
et al. Annexin 1 released by necrotic human glioblastoma cells stimulates
tumor cell growth through the formyl peptide receptor 1. Am J Pathol.
2011;179:1504–12.
36. Sveinbjornsson B, Rasmuson A, Baryawno N, Wan M, Pettersen I, Ponthan F,
Orrego A, Haeggstrom JZ, Johnsen JI, Kogner P. Expression of enzymes and
receptors of the leukotriene pathway in human neuroblastoma promotes
tumor survival and provides a target for therapy. FASEB J. 2008;22:3525–36.
37. Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2:
1125–31.
38. He Y, Zha J, Wang Y, Liu W, Yang X, Yu P. Tissue damage-associated
“danger signals” influence T-cell responses that promote the progression of
preneoplasia to cancer. Cancer Res. 2013;73:629–39.
39. Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT. Antagonism of
human formyl peptide receptor 1 with natural compounds and their
synthetic derivatives. Int Immunopharmacol. 2016;37:43–58.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Snapkov et al. BMC Cancer  (2016) 16:490 Page 12 of 12
